Vericel Corporation (VCEL) PT Raised to $20 at BTIG

Go back to Vericel Corporation (VCEL) PT Raised to $20 at BTIG

Vericel Corporation (VCEL) PT Raised to $18 at Needham & Company

November 6, 2018 12:43 PM EST

Needham & Company analyst Chad Messer raised the price target on Vericel Corporation (NASDAQ: VCEL) to $18.00 (from $14.00) while maintaining a Buy rating.

... More

Pre-Open Movers 11/06: (VCEL) (ELF) (MYL) Higher; (ONCS) (FTDR) (RL) Lower (more...)

November 6, 2018 9:24 AM EST

Today's Pre-Open Stock Movers

OncoSec Medical Incorporated (NASDAQ: ONCS) 56.9% LOWER; reported preliminary data from KEYNOTE-695, a global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVO (tavokinogene telseplasmid / IL-12) with intravenous KEYTRUDA® (pembrolizumab) in patients with unresectable, advanced melanoma. Eligible patients had refractory, locally advanced or metastatic disease defined as unresectable Stage... More

Vericel (VCEL) Tops Q3 EPS by 9c, Revenues Beat; Raises FY18 Revenue Guidance Above Consensus

November 6, 2018 7:41 AM EST

Vericel (NASDAQ: VCEL) reported Q3 EPS of ($0.02), $0.09 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $22.5 million versus the consensus estimate of $18.14 million.

We achieved record third quarter revenues and our consistently strong revenue growth has generated significant improvements in... More